Oedème maculaire et occlusions veineuses
In the French clinical setting, DEX implant demonstrated efficacy and safety similar to those of phase 3 trials.
- BCVA significantly increased at all follow-up visits
- CRT was reduced at all follow-up visits
- DEX implant was well tolerated
- The most frequently reported AEs were cataract and IOP increase, consistent with previous observations
